LOS ANGELES--(BUSINESS WIRE)--Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the addition of two independent members to the Company’s board of directors. The Company welcomes back health care specialist Kerry Weems to the board as an independent director and chairman of the Nominating and Governance Committee, as well as corporate finance expert Paul Pelosi, Jr. as an independent director.
A nationally respected expert in health policy and government finance, Mr. Weems has served with distinction in the field of health care, including nearly 28 years in the Federal government, as Acting Administrator of the Centers for Medicare and Medicaid Services (CMS). Mr. Weems is currently Chief Executive Officer of TwinMed, a national medical supply distributor in Los Angeles.
Mr. Paul Pelosi, Jr., has many years of experience in advising companies in the areas of finance, infrastructure, and sustainability. Mr. Pelosi has background in business law, public policy, the public securities markets, and has worked with numerous emerging microcap companies to develop sound business protocols. Mr. Pelosi has been a private investor and an independent adviser to emerging companies, including NASA Ames Research Center, Global Emerging Markets and AirPatrol Corporation. Mr. Pelosi graduated from Georgetown Law Center, has been a member of the California State Bar since 1996, and Real Estate Broker since 2002.
About Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.
Forward Looking Statement
This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.